BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adduri RS, Katamoni R, Pandilla R, Madana SN, Paripati AK, Kotapalli V, Bashyam MD. TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in esophageal cancer in India. PLoS One 2014;9:e114002. [PMID: 25436609 DOI: 10.1371/journal.pone.0114002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang W, Han Y, Zhao X, Duan L, Zhou W, Wang X, Shi G, Che Y, Zhang Y, Liu J, Zhang H, Zhao Q, Hong L, Fan D. Advances in prognostic biomarkers for esophageal cancer. Expert Review of Molecular Diagnostics 2019;19:109-19. [DOI: 10.1080/14737159.2019.1563485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lin YM, Shao J, Yin XH, Huang C, Jia XW, Yuan YD, Wu CJ, Zhen EM, Yao ZX, Zeng XT, Liu RH. Meta-Analysis Results on the Association Between TP53 Codon 72 Polymorphism With the Susceptibility to Oral Cancer. Front Physiol 2018;9:1014. [PMID: 30116199 DOI: 10.3389/fphys.2018.01014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Adduri RSR, George SA, Kavadipula P, Bashyam MD. SMARCD1 is a transcriptional target of specific non‐hotspot mutant p53 forms. J Cell Physiol 2020;235:4559-70. [DOI: 10.1002/jcp.29332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Hussein AA, Forouzanfar T, Bloemena E, de Visscher J, Brakenhoff RH, Leemans CR, Helder MN. A review of the most promising biomarkers for early diagnosis and prognosis prediction of tongue squamous cell carcinoma. Br J Cancer 2018;119:724-36. [PMID: 30131545 DOI: 10.1038/s41416-018-0233-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 9.3] [Reference Citation Analysis]
5 Nagam SL, Katta S, Prasad VV. Gender specific association of TP53 polymorphisms (EX4 215G>C Arg72Pro, IVS3+40-41ins16, and IVS6+62G>A), with risk of oral cancer subtypes and overall survival of the patients. Mol Carcinog 2017;56:895-912. [PMID: 27532290 DOI: 10.1002/mc.22543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zarate AM, Don J, Secchi D, Carrica A, Galindez Costa F, Panico R, Brusa M, Barra JL, Brunotto M. Study of the TP53 codon 72 polymorphism in oral cancer and oral potentially malignant disorders in Argentine patients. Tumour Biol 2017;39:1010428317699113. [PMID: 28459200 DOI: 10.1177/1010428317699113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Sun Z, Gao W, Cui JT. Effect of TP53 rs1042522 on the susceptibility of patients to oral squamous cell carcinoma and oral leukoplakia: a meta-analysis. BMC Oral Health 2018;18:143. [PMID: 30126398 DOI: 10.1186/s12903-018-0603-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]